| Type | Title | Date Released | |
|---|---|---|---|
10-Q | Form 10-Q | ||
8-K | Filana Therapeutics Reports Q3 2026 Financial Results and Prepares for Phase 2a Simufilam Trial | ||
8-K | U.S. Court of Appeals Vacates Class Certification in Filana Therapeutics Securities Class Action | ||
4 | Barry Richard (Reporting) | ||
4 | Barry Richard (Reporting) | ||
8-K | Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam for Phase 2a Study in TSC-Related Epilepsy | ||
8-K | Filana Therapeutics Receives Nasdaq Minimum Bid Price Deficiency Notice | ||
10-Q | Form 10-Q | ||
8-K | Filana Therapeutics Reports Q2 2026 Financial Results and Business Update | ||
8-K | Filana Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders | ||
10-Q | Form 10-Q | ||
8-K | Filana Therapeutics Reports Q1 2026 Financial Results and Corporate Rebranding |
